Martingale Asset Management L P Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Martingale Asset Management L P decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 56.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,520 shares of the biopharmaceutical company’s stock after selling 19,773 shares during the quarter. Martingale Asset Management L P’s holdings in Agios Pharmaceuticals were worth $510,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in AGIO. Vanguard Group Inc. boosted its position in shares of Agios Pharmaceuticals by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after purchasing an additional 85,339 shares during the period. State Street Corp boosted its holdings in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after acquiring an additional 216,484 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares during the period. Fisher Asset Management LLC grew its position in shares of Agios Pharmaceuticals by 12.3% during the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company’s stock worth $31,567,000 after acquiring an additional 105,333 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in shares of Agios Pharmaceuticals by 27.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 499,134 shares of the biopharmaceutical company’s stock valued at $16,402,000 after acquiring an additional 107,292 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AGIO. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Trading Up 5.5 %

Shares of AGIO opened at $26.70 on Friday. The stock’s 50 day moving average is $31.39 and its two-hundred day moving average is $39.24. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The firm has a market capitalization of $1.53 billion, a PE ratio of 2.35 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the company’s stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.